{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:29Z","timestamp":1788675449009,"version":"build-2803163510"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) improve outcomes across malignancies but can cause immune-related adverse events (irAEs), notably myocarditis, with case-fatality up to 50%<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed five patients with potential ICI-associated myocarditis treated at Mayo Clinic Florida (2019\u20132024) and summarize the existing literature. Cases were retrospectively categorized as definite, probable, or possible myocarditis according to cardiac magnetic resonance (CMR) findings and histopathology when available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 74 years, and four of the five patients were male. Myocarditis developed between 5 and 30 days after initiation of anti\u2013PD-1 therapy. Presentations included dyspnea (three patients), chest pain (one patient), and asymptomatic troponin elevation detected on routine monitoring (one patient). Troponin T elevation above the 99th percentile was seen in all five cases (normal &lt;= 15 ng\/L). Electrocardiograms (ECG) demonstrated conduction abnormalities or ventricular ectopy in each patient. Left ventricular ejection fraction was preserved in four patients and severely reduced in one.<\/jats:p>\n                    <jats:p>CMR provided findings supportive of myocarditis in two of the five cases, while one endomyocardial biopsy (EMB) was performed and did not demonstrate active inflammation. Based on predefined criteria, one case was classified as definite myocarditis, one as probable, and three as possible ICI-associated myocarditis.<\/jats:p>\n                    <jats:p>All five patients received corticosteroid therapy. Two required escalation of immunosuppression. One patient developed concurrent myasthenia gravis, consistent with myocarditis\u2013myositis\u2013myasthenia (MMM) overlap, and underwent plasmapheresis for the neuromuscular component. Three patients recovered. Two patients died during follow-up; in both cases, myocarditis was considered a contributing factor, although direct causality could not be definitively established.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/rjim-2026-0013","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:58:01Z","timestamp":1782107881000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Inhibitor\u2013Associated Myocarditis: A Retrospective Case Series"],"prefix":"10.2478","author":[{"given":"Michael Acevedo","family":"Monsanto","sequence":"first","affiliation":[{"name":"Department of Medicine , Mayo Clinic , Jacksonville , Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine , Mayo Clinic , Jacksonville , Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan M.","family":"Chirila","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine , Mayo Clinic , Jacksonville , FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulamy","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Department of Medicine , Mayo Clinic , Jacksonville , Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camily Morales","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Medicine , Mayo Clinic , Jacksonville , Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Zuberi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine , Mayo Clinic , Jacksonville , FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026081913080248307_j_rjim-2026-0013_ref_001","doi-asserted-by":"crossref","unstructured":"SIEGEL RL, GIAQUINTO AN, JEMAL A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):7\u201333.","DOI":"10.3322\/caac.21820"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_002","doi-asserted-by":"crossref","unstructured":"POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u2013168.","DOI":"10.1056\/NEJMra1703481"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_003","doi-asserted-by":"crossref","unstructured":"SCHNEIDER BJ, NAIDOO J, SANTOMASSO BD, LACCHETTI C, ADKINS S, ANADKAT M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u20134126.","DOI":"10.1200\/JCO.21.01440"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_004","doi-asserted-by":"crossref","unstructured":"MAHMOOD SS, FRADLEY MG, COHEN JV, NOHRIA A, REYNOLDS KL, HEINZERLING LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u20131764.","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_005","doi-asserted-by":"crossref","unstructured":"PALASKAS N, LOPEZ-MATTEI J, DURAND JB, ILIESCU C, DESWAL A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.","DOI":"10.1161\/JAHA.119.013757"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_006","doi-asserted-by":"crossref","unstructured":"LIPE DN, QDAISAT A, KRISHNAMANI PP, PARIKH R, MURTHY P, PATEL M, et al. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024;14(16):1794.","DOI":"10.3390\/diagnostics14161794"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_007","doi-asserted-by":"crossref","unstructured":"BAIK AH, OLUWOLE OO, JOHNSON DB, SHAH N, SALEM JE, TSAI KK, et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780\u20131801.","DOI":"10.1161\/CIRCRESAHA.120.315894"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_008","doi-asserted-by":"crossref","unstructured":"FERREIRA VM, SCHULZ-MENGER J, HOLMVANG G, KRAMER CM, CARBONE I, SECHTEM U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: updated Lake Louise criteria. J Am Coll Cardiol. 2018;72(24):3158\u20133176.","DOI":"10.1016\/j.jacc.2018.09.072"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_009","doi-asserted-by":"crossref","unstructured":"ROSSI VA, GAWINECKA J, DIMITRIOU F, et al. Value of troponin T versus troponin I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis. ESC Heart Fail. 2023;10(4):2680\u20132685.","DOI":"10.1002\/ehf2.14360"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_010","doi-asserted-by":"crossref","unstructured":"CAFORIO ALP, PANKUWEIT S, ARBUSTINI E, BASSO C, GIMENO-BLANES J, FELIX SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis. Eur Heart J. 2013;34(33):2636\u20132648.","DOI":"10.1093\/eurheartj\/eht210"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_011","doi-asserted-by":"crossref","unstructured":"DRAZNER MH, BOZKURT B, COOPER LT, AGGARWAL NR, BASSO C, BHAVE NM, et al. 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis. J Am Coll Cardiol. 2024;83:In press.","DOI":"10.1016\/j.jacc.2024.10.080"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_012","unstructured":"POWER JR, DOLLADILLE C, OZBAY B, PROCUREUR A, EDERHY S, PALASKAS NL, et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2025;46:In press."},{"key":"2026081913080248307_j_rjim-2026-0013_ref_013","doi-asserted-by":"crossref","unstructured":"AXELROD ML, MEIJERS WC, SCREEVER EM, QIN J, CARROLL MG, SUN X, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7936):818\u2013824.","DOI":"10.1038\/s41586-022-05432-3"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_014","doi-asserted-by":"crossref","unstructured":"CHO J, KIM HS, KU BM, CHOI YL, CRISTESCU R, HAN J, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol. 2019;37(24):2162\u20132170.","DOI":"10.1200\/JCO.2017.77.3184"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_015","doi-asserted-by":"crossref","unstructured":"SHELLY S, AGMON-LEVIN N, ALTMAN A, SHOENFELD Y. Thymoma and autoimmunity. Autoimmun Rev. 2011;10(12):753\u2013758.","DOI":"10.1038\/cmi.2010.74"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_016","doi-asserted-by":"crossref","unstructured":"PALASKAS NL, SIDDIQUI BA, DESWAL A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 2024;6(5):800\u2013803.","DOI":"10.1016\/j.jaccao.2024.07.002"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_017","doi-asserted-by":"crossref","unstructured":"SALEM JE, ALLENBACH Y, VOZY A, BRECHOT N, JOHNSON DB, MOSLEHI JJ, et al. Abatacept for severe immune checkpoint inhibitor\u2013associated myocarditis. N Engl J Med. 2019;380(24):2377\u20132379.","DOI":"10.1056\/NEJMc1901677"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_018","doi-asserted-by":"crossref","unstructured":"S\u00c1NCHEZ-CAMACHO A, FERREIRA VM, LYON AR, et al. Management of immune-related myocarditis, myositis and myasthenia gravis overlap syndrome. Front Immunol. 2025;16:1597259.","DOI":"10.3389\/fimmu.2025.1597259"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_019","doi-asserted-by":"crossref","unstructured":"SUZUKI S, UTSUGISAWA K, YOSHIKAWA H, NAGANE Y, SATOH T, KUWANA M, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009;66(11):1334\u20131338.","DOI":"10.1001\/archneurol.2009.229"},{"key":"2026081913080248307_j_rjim-2026-0013_ref_020","doi-asserted-by":"crossref","unstructured":"GANATRA S, BARAC A, ARMENIAN S, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton's tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance. J Am Coll Cardiol. 2026;87(5):654\u2013682.","DOI":"10.1016\/j.jacc.2025.10.018"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2026-0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:09:42Z","timestamp":1787144982000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2026-0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":20,"alternative-id":["10.2478\/rjim-2026-0013"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2026-0013","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}